Success Metrics

Clinical Success Rate
94.4%

Based on 17 completed trials

Completion Rate
94%(17/18)
Active Trials
4(13%)
Results Posted
12%(2 trials)
Terminated
1(3%)

Phase Distribution

Ph early_phase_1
1
3%
Ph phase_1
5
16%
Ph phase_4
10
32%
Ph phase_3
5
16%
Ph phase_2
1
3%
Ph not_applicable
7
23%

Phase Distribution

6

Early Stage

1

Mid Stage

15

Late Stage

Phase Distribution29 total trials
Early Phase 1First-in-human
1(3.4%)
Phase 1Safety & dosage
5(17.2%)
Phase 2Efficacy & side effects
1(3.4%)
Phase 3Large-scale testing
5(17.2%)
Phase 4Post-market surveillance
10(34.5%)
N/ANon-phased studies
7(24.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.0%

17 of 20 finished

Non-Completion Rate

15.0%

3 ended early

Currently Active

4

trials recruiting

Total Trials

31

all time

Status Distribution
Active(4)
Completed(17)
Terminated(3)
Other(7)

Detailed Status

Completed17
unknown7
Recruiting2
Withdrawn2
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
4
Success Rate
94.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.4%)
Phase 15 (17.2%)
Phase 21 (3.4%)
Phase 35 (17.2%)
Phase 410 (34.5%)
N/A7 (24.1%)

Trials by Status

recruiting26%
withdrawn26%
unknown723%
active_not_recruiting26%
terminated13%
completed1755%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT07304466Not Applicable

Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation

Recruiting
NCT07366710Not Applicable

Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET

Active Not Recruiting
NCT06416969Early Phase 1

Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

Recruiting
NCT03000946Phase 3

Prevention of Postoperative Pancreatic Fistula by Somatostatin

Completed
NCT03241706Phase 1

Liver Glycogen and Hypoglycemia in Humans

Active Not Recruiting
NCT03998293Phase 4

Direct Measurement of Proinsulin Clearance in Humans

Withdrawn
NCT03998709Phase 4

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

Withdrawn
NCT02748369Phase 1

In Vivo Assessment of Cellular Metabolism in Humans

Completed
NCT04358016Phase 4

Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

Completed
NCT03349424Phase 4

Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy

Completed
NCT00786825Phase 2

Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla

Completed
NCT04107428Phase 4

Somatostatin in Living Donor Liver Transplantation

Unknown
NCT04010669Phase 3

The Role of Somatostatin in the Hemodynamics of the Hepatic Circulation in Patients Undergoing Liver Resection

Unknown
NCT03846180

Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

Completed
NCT02836353Not Applicable

Metabolic Consequences of Gastrointestinal Surgery

Terminated
NCT00966355Phase 4

Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding

Completed
NCT00793741

Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

Completed
NCT02882347Phase 3

The Effect of Somatostatin for Treatment of Post Hepatectomy Liver Failure (PHLF)

Unknown
NCT02757703Phase 4

Vasoactive Drugs in Real World Practice

Completed
NCT02026973Phase 1

Impact of Endogenous E2 on SSI and GH Rebound

Completed

Drug Details

Intervention Type
DRUG
Total Trials
31